We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

OPY:NYSEOppenheimer Holdings, Inc. Analysis

Data as of 2026-04-22 - not real-time

$118.02

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Oppenheimer Holdings is trading at $118.02, comfortably above the 20‑day ($101.23), 50‑day ($92.34) and 200‑day ($77.58) moving averages, confirming a strong bullish bias. Technical momentum is reinforced by a bullish MACD crossover (line $7.66 above signal $6.21) and a price near the recent resistance of $118.77, while an RSI of 84.7 flags the stock as overbought in the short run.
Fundamentally, the stock appears dramatically undervalued: a trailing P/E of 9.1 versus the industry average of 17.6, a price‑to‑book of 1.26, and a DCF‑derived fair value of $481.37 suggest a large upside potential. Revenue is expanding at a robust 27.8% with a 91% gross margin and 35% operating margin, and the balance sheet is net‑cash positive (cash $1.45B vs debt $1.23B). The dividend yield of 0.63% is supported by a modest 5.5% payout ratio, indicating sustainability. Despite the high leverage ratio (debt‑to‑equity 123%), the company’s strong cash generation and low payout provide a cushion, though forward earnings appear compressed, inflating the forward P/E to 46.1. The stock’s 30‑day volatility of ~30% and beta around 1.07 signal moderate market sensitivity, while stable volume and a market cap of $1.26B mitigate liquidity concerns.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI indicating overbought conditions
  • Price approaching short‑term resistance
  • Bullish MACD and trend still intact

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation gap (low P/E vs industry, DCF upside)
  • Strong revenue growth and high margins
  • Net‑cash position and sustainable dividend

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Durable cash generation and low payout ratio
  • Undervalued relative to peers with upside potential
  • Exposure to capital‑markets franchise with growth opportunities

Key Metrics & Analysis

Financial Health

Revenue Growth27.80%
Profit Margin9.56%
P/E Ratio9.1
ROE16.02%
ROA4.17%
Debt/Equity123.26
P/B Ratio1.3
Op. Cash Flow$188.8M
Industry P/E17.6

Technical Analysis

TrendBullish
RSI84.7
Support$83.60
Resistance$118.77
MA 20$101.23
MA 50$92.34
MA 200$77.58
MACDBullish
VolumeStable
Fear & Greed Index86.98

Valuation

Fair Value$481.37
GradeUndervalued
TypeBlend
Dividend Yield0.63%

Risk Assessment

Beta1.07
Volatility29.67%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.